A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of Chemoresistance and Immune Evasion

Brief summary (registry, in English)

Colorectal cancer (CRC) has shifted toward a patient-personalized precision medicine paradigm; however, the high heterogeneity and complex tumor microenvironment (TME) of CRC restrict the development of individualized therapy, and existing preclinical models and multi-omics technologies are insufficient to broadly benefit patients. Building on previous research, this project intends to use 3D multicellular bioprinting (3DMP) to incorporate key TME components-cancer-associated fibroblasts (CAFs) and PBMC immune cells-to construct patient-derived CRC-CAFs/PBMC 3DMP models, aiming to apply them to personalized clinical drug screening and prognosis prediction, and to combine them with multi-omics technologies to advance preclinical research on CRC. The implementation of this study will help address the bottleneck of the lack of broadly applicable preclinical models for advancing CRC precision therapy. It has major clinical translational value, will bring significant changes to CRC preclinical research platforms, and will help promote the development of cancer precision medicine.

What you commit to

• Study type: Observational
• Planned participants: 60
• From 24 May 2025 to the primary completion date, 1 Nov 2026
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.